Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects

Federica Mori, Maria Ferraiuolo, Raffaela Santoro, Andrea Sacconi, Frauke Inger Karen Goeman, Matteo Pallocca, Claudio Pulito, Etleva Korita, Maurizio Fanciulli, Paola Muti, Giovanni Blandino, Sabrina Strano

Research output: Contribution to journalArticlepeer-review

Abstract

We have previously shown that melatonin exerts tumor suppressor activities by inducing the p38-p53 axis. This occurred within a few hours while no data are available on how melatonin pathway can be sustained on the long term. Here we show that miR-24, which has been demonstrated to target genes involved in the DNA repair process, targets p38, p53, PML and H2AX simultaneously. We show that long-term treatment with melatonin can decrease miR-24 levels post-transcriptionally, which pairs with a long-wave regulation of genes involved in cell proliferation, DNA damage, RNA metabolism and cell shape and transformation. Moreover, we show that melatonin can inhibit cell proliferation and migration, at least in part, by downregulating miR-24. Furthermore, we propose the involvement of hnRNP A1, which is downregulated by melatonin and involved in miRNA processing, in the regulation of miR-24 levels by melatonin. We conclude showing that miR-24 is upregulated in colon, breast and head and neck datasets and its levels negatively correlate with overall survival.

Original languageEnglish
Pages (from-to)20532-20548
Number of pages17
JournalOncotarget
Volume7
Issue number15
DOIs
Publication statusPublished - Apr 12 2016

Keywords

  • Melatonin
  • MiR-24
  • P53
  • PML
  • RNA-Seq

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects'. Together they form a unique fingerprint.

Cite this